Windtree announced results from phase 2 study of lucinactant for COVID-19 associated ARDS and Lung Injury
On Mar. 22, 2022, Windtree Therapeutics announced results from its Phase 2 study of lucinactant (KL4 surfactant) for…
On Mar. 22, 2022, Windtree Therapeutics announced results from its Phase 2 study of lucinactant (KL4 surfactant) for…
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
On Mar. 21, 2022, Moderna announced announced a supply agreement with the Swiss Federal Government for seven million…
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
On Mar. 17, 2022, Moderna announced that Health Canada had approved the use of Moderna’s mRNA COVID-19 vaccine,…
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax™ (heat stable COVID-19…
On Mar. 17, 2022, Moderna announced that it had submitted a request to the U.S. Food and Drug…
On Mar. 16, 2022, Moderna announced an agreement with the Ministry of Health, Labour and Welfare of Japan…
On Mar. 15, 2022, Pfizer and BioNTech announced the companies had submitted an application to the U.S. Food…
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
On Mar. 11, 2022, the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine was recommended by the Centers for Disease Control and…
On Mar. 10, 2022, a COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to…
On Mar. 10, 2022, Oragenics announced that it had entered into an agreement with KBI Biopharma for the…
On Mar. 10, 2022, Moderna announced that the first participant had been dosed in the Phase 2 study…
On Mar. 10, 2022, schools with mandatory masking during the Delta surge had approximately 72% fewer cases of…
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of Protease…
On Mar. 9, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced a clinical…
On Mar. 7, 2022, Innovation Pharma announced the Company was conducting full data analysis of the Phase 2…
On Mar. 7, 2022, researchers from the University of Oxford have used data from UK Biobank participants to…
On Mar. 4, 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that COVID-19 vaccination coverage with…
On Mar. 3, 2022, a study carried out in southwestern Ontario identified a highly mutated variant of SARS-CoV-2…
On Mar. 3, 2022, the World Health Organization (WHO) and the Medicines Patent Pool (MPP) jointly welcomed the announcement…
On Mar. 2, 2022, Sorrento Therapeutics announced that its Phase I study of intranasal (IN) STI-9199 (COVISHIELDTM IN) has…
On Mar. 1, 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that two doses of Pfizer-BioNTech…
On Feb. 24, 2022, Novavax shared extended analysis from its pivotal Phase 3 clinical trial conducted in the…
On Feb. 24, 2022, Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use…
On Feb. 24, 2022, BioNTech announced that the Committee for Medicinal Products for Human Use of the European…
On Feb. 24, 2022, Medicago and GlaxoSmithKline announced that Health Canada had granted approval for COVIFENZ, COVID-19 vaccine,…
On Feb. 23, 2022, Sanofi and GSK announced that they planned to submit data from both their booster…
On Feb. 23, 2022, Moderna and Thermo Fisher Scientific announced a 15-year strategic collaboration agreement to enable dedicated…